从有效阿尔茨海默氏症药物重定位药物 (DREAM) 研究的基于人口的验证结果
Rishi J Desai1, Vijay R Varma2, Mufaddal Mahesri1
1Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital & Harvard Medical School, Boston, Massachusetts, USA.
Clinical pharmacology and therapeutics
|February 12, 2025
概括
某些血压药物可能会延迟阿尔茨海默病和相关痴呆症 (ADRD) 的发病. 在这项观察性研究中,甲酸显示降低了风险,而阿米洛里德则表明了潜在的益处.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 阿尔茨海默病和相关痴呆症 (ADRD) 构成了重大的公共卫生挑战.
- 代谢失调越来越被认为是ADRD发病的关键因素.
- 重新利用针对代谢途径的现有药物提供了一个潜在的治疗策略.
研究的目的:
- 调查是否已批准用于其他疾病的药物,但针对ADRD的代谢驱动因素,与ADRD的延迟发病有关.
- 用现实世界医疗保健数据评估特定药物类别与ADRD风险之间的关联.
主要方法:
- 使用美国医疗保险和英国CPRD数据进行了新用户队列研究.
- 采用四种不同的分析方法来缓解信息审查,反向因果关系和结果错误分类等偏见.
- 评估了10种药物对,包括化胺与二二二二二和化与三二.
主要成果:
- 在四项分析中,三项分析显示,甲胺显著降低了ADRD风险 (合并HR在0.75至0.83之间).
- 阿米洛里德在三项分析中也表明了潜在的风险降低,尽管精度较低 (合并HRs在0.61到0.86之间).
- 其他被评估的药物没有显著的关联或缺乏足够的准确性来得出最终的结论.
结论:
- 某些抗高血压药物,特别是甲和潜在的阿米洛里德,可能与阿尔茨海默氏症和相关痴呆症的延迟发病有关.
- 这些发现凸显了重定向药物针对代谢途径在ADRD预防中的潜力.
- 需要进一步的复制研究来证实这些关联并探索潜在的机制.
相关概念视频
01:22Alzheimer's Disease: Treatment
155
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
155
01:26Alzheimer's Disease: Overview
432
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
432
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95
01:26Drug Discovery: Overview
7.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.4K